Catalytic activity and stereoselectivity of engineered phosphotriesterases towards structurally different nerve agents in vitro.


Journal

Archives of toxicology
ISSN: 1432-0738
Titre abrégé: Arch Toxicol
Pays: Germany
ID NLM: 0417615

Informations de publication

Date de publication:
08 2021
Historique:
received: 07 05 2021
accepted: 15 06 2021
pubmed: 24 6 2021
medline: 12 1 2022
entrez: 23 6 2021
Statut: ppublish

Résumé

Highly toxic organophosphorus nerve agents, especially the extremely stable and persistent V-type agents such as VX, still pose a threat to the human population and require effective medical countermeasures. Engineered mutants of the Brevundimonas diminuta phosphotriesterase (BdPTE) exhibit enhanced catalytic activities and have demonstrated detoxification in animal models, however, substrate specificity and fast plasma clearance limit their medical applicability. To allow better assessment of their substrate profiles, we have thoroughly investigated the catalytic efficacies of five BdPTE mutants with 17 different nerve agents using an AChE inhibition assay. In addition, we studied one BdPTE version that was fused with structurally disordered PAS polypeptides to enable delayed plasma clearance and one bispecific BdPTE with broadened substrate spectrum composed of two functionally distinct subunits connected by a PAS linker. Measured k

Identifiants

pubmed: 34160649
doi: 10.1007/s00204-021-03094-0
pii: 10.1007/s00204-021-03094-0
pmc: PMC8298220
doi:

Substances chimiques

Nerve Agents 0
Phosphoric Triester Hydrolases EC 3.1.8.-

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2815-2823

Informations de copyright

© 2021. The Author(s).

Références

Ashani Y, Leader H, Aggarwal N, Silman I, Worek F, Sussman J, Goldsmith M (2016) In vitro evaluation of the catalytic activity of paraoxonases and phosphotriesterases predicts the enzyme circulatory levels required for in vivo protection against organophosphate intoxications. Chem Biol Interact 259:252–256
pubmed: 27163850 pmcid: 5097891 doi: 10.1016/j.cbi.2016.04.039
Benschop HP, de Jong LPA (1988) Nerve agent stereoisomers: analysis, isolation, and toxicology. Acc Chem Res 21:368–374
doi: 10.1021/ar00154a003
Bierwisch A, Zengerle M, Thiermann H, Kubik S, Worek F (2014) Detoxification of alkyl methylphosphonofluoridates by an oxime-substituted β-cyclodextrin—an in vitro structure-activity study. Toxicol Lett 224:209–214
pubmed: 24185128 doi: 10.1016/j.toxlet.2013.10.024 pmcid: 24185128
Bigley A, Xu C, Henderson T, Harvey S, Raushel F (2013) Enzymatic neutralization of the chemical warfare agent VX: evolution of phosphotriesterase for phosphorothiolate hydrolysis. J Am Chem Soc 135:10426–10432
pubmed: 23789980 pmcid: 3747228 doi: 10.1021/ja402832z
Bigley A, Mabanglo M, Harvey S, Raushel F (2015) Variants of phosphotriesterase for the enhanced detoxification of the chemical warfare agent VR. Biochemistry 54:5502–5512
pubmed: 26274608 doi: 10.1021/acs.biochem.5b00629 pmcid: 26274608
Binder U, Skerra A (2017) PASylation®: a versatile technology to extend drug delivery. Curr Opin Colloid Interface Sci 31:10–17
doi: 10.1016/j.cocis.2017.06.004
Chen-Goodspeed M, Hong S, Raushel F, Sogorb M, Wu F (2001a) Structural determinants of the substrate and stereochemical specificity of phosphotriesterase. Biochemistry 40:1325–1331
pubmed: 11170459 doi: 10.1021/bi001548l
Chen-Goodspeed M, Sogorb M, Wu F, Raushel F (2001b) Enhancement, relaxation, and reversal of the stereoselectivity for phosphotriesterase by rational evolution of active site residues. Biochemistry 40:1332–1339
pubmed: 11170460 doi: 10.1021/bi001549d pmcid: 11170460
Cherny I, Greisen P, Ashani Y, Khare S, Oberdorfer G, Leader H, Baker D, Tawfik D (2013) Engineering V-type nerve agents detoxifying enzymes using computationally focused libraries. ACS Chem Biol 8:2394–2403
pubmed: 24041203 doi: 10.1021/cb4004892 pmcid: 24041203
Costanzi S, Machado JH, Mitchell M (2018) Nerve agents: what they are, how they work, how to counter them. ACS Chem Neurosci 9:873–885
pubmed: 29664277 doi: 10.1021/acschemneuro.8b00148 pmcid: 29664277
Despotović D, Aharon E, Dubovetskyi A, Leader H, Ashani Y, Tawfik D (2019) A mixture of three engineered phosphotriesterases enables rapid detoxification of the entire spectrum of known threat nerve agents. Protein Eng Des Sel 32:169–174
pubmed: 31612205 doi: 10.1093/protein/gzz039 pmcid: 31612205
Dodge J, Mitchell C, Hanahan D (1963) The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. Arch Biochem Biophys 100:119–130
pubmed: 14028302 doi: 10.1016/0003-9861(63)90042-0 pmcid: 14028302
Escher B, Köhler A, Job L, Worek F, Skerra A (2020) Translating the concept of bispecific antibodies to engineering heterodimeric phosphotriesterases with broad organophosphate substrate recognition. Biochemistry 59:4395–4406
pubmed: 33146522 doi: 10.1021/acs.biochem.0c00751 pmcid: 33146522
Fling S, Gregerson D (1986) Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea. Anal Biochem 155:83–88
pubmed: 3454661 doi: 10.1016/0003-2697(86)90228-9 pmcid: 3454661
Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins AR, Bairoch A (2005) The proteomics protocols handbook: protein identification and analysis tools on the ExPASy Server. Humana Press Inc., Totowa
Gebauer M, Skerra A (2018) Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action. Bioorg Med Chem 26:2882–2887
pubmed: 29102080 doi: 10.1016/j.bmc.2017.09.016 pmcid: 29102080
Goldsmith M, Eckstein S, Ashani Y, Greisen P, Leader H, Sussman J, Aggarwal N, Ovchinnikov S, Tawfik D, Baker D, Thiermann H, Worek F (2016) Catalytic efficiencies of directly evolved phosphotriesterase variants with structurally different organophosphorus compounds in vitro. Arch Toxicol 90:2711–2724
pubmed: 26612364 doi: 10.1007/s00204-015-1626-2 pmcid: 26612364
Goldsmith M, Aggarwal N, Ashani Y, Jubran H, Greisen P, Ovchinnikov S, Leader H, Baker D, Sussman J, Goldenzweig A, Fleishman S, Tawfik D (2017) Overcoming an optimization plateau in the directed evolution of highly efficient nerve agent bioscavengers. Protein Eng Des Sel 30:333–345
pubmed: 28159998 doi: 10.1093/protein/gzx003 pmcid: 28159998
Grob D (1963) Anticholinesterase intoxication in man and its treatment. In: Koelle GB (ed) Cholinesterases and anticholinesterase agents. Springer, Berlin, pp 989–1027
doi: 10.1007/978-3-642-99875-1_22
Holmstedt B (1959) Pharmacology of organophosphorus cholinesterase inhibitors. Pharmacol Rev 11:567–688
pubmed: 14402820 pmcid: 14402820
Job L, Köhler A, Escher B, Worek F, Skerra A (2020) A catalytic bioscavenger with improved stability and reduced susceptibility to oxidation for treatment of acute poisoning with neurotoxic organophosphorus compounds. Toxicol Lett 321:138–145
pubmed: 31891759 doi: 10.1016/j.toxlet.2019.12.030 pmcid: 31891759
John H, van der Schans MJ, Koller M, Spruit HET, Worek F, Thiermann H, Noort D (2018) Fatal sarin poisoning in Syria 2013: forensic verification within an international laboratory network. Forensic Toxicol 36:61–71
pubmed: 29367863 doi: 10.1007/s11419-017-0376-7 pmcid: 29367863
Marrs TC, Sellström A (2007) The use of benzodiazepines in organophosphorus nerve agent intoxication. In: Marrs TC, Maynard RL, Sidell FR (eds) Chemical warfare agents: toxicology and treatment, 2nd edn. Wiley, Chichester, pp 331–342
doi: 10.1002/9780470060032.ch16
Nachon F, Brazzolotto X, Trovaslet M, Masson P (2013) Progress in the development of enzyme-based nerve agent bioscavengers. Chem Biol Interact 206:536–544
pubmed: 23811386 doi: 10.1016/j.cbi.2013.06.012 pmcid: 23811386
Novikov B, Grimsley J, Kern R, Wild J, Wales M (2010) Improved pharmacokinetics and immunogenicity profile of organophosphorus hydrolase by chemical modification with polyethylene glycol. J Control Release 146:318–325
pubmed: 20547191 doi: 10.1016/j.jconrel.2010.06.003 pmcid: 20547191
Reiter G, Müller S, Hill I, Weatherby K, Thiermann H, Worek F, Mikler J (2015) In vitro and in vivo toxicological studies of V nerve agents: molecular and stereoselective aspects. Toxicol Lett 232:438–448
pubmed: 25448275 doi: 10.1016/j.toxlet.2014.11.010 pmcid: 25448275
Rice H (2016) Toxicology of organophosphorus nerve agents. In: Worek F, Jenner J, Thiermann H (eds) Chemical warfare toxicology. Royal Society of Chemistry, Cambridge, pp 81–116
doi: 10.1039/9781782622413-00081
Roodveldt C, Tawfik D (2005) Directed evolution of phosphotriesterase from Pseudomonas diminuta for heterologous expression in Escherichia coli results in stabilization of the metal-free state. Protein Eng Des Sel 18:51–58
pubmed: 15790580 doi: 10.1093/protein/gzi005 pmcid: 15790580
Schlapschy M, Binder U, Börger C, Theobald I, Wachinger K, Kisling S, Haller D, Skerra A (2013) PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng Des Sel 26:489–501
pubmed: 23754528 pmcid: 3715784 doi: 10.1093/protein/gzt023
Schmidt T, Skerra A (2007) The Strep-tag system for one-step purification and high-affinity detection or capturing of proteins. Nat Protoc 2:1528–1535
pubmed: 17571060 doi: 10.1038/nprot.2007.209 pmcid: 17571060
Steindl D, Boehmerle W, Körner R, Praeger D, Haug M, Nee J, Schreiber A, Scheibe F, Demin K, Jacoby P, Tauber R, Hartwig S, Endres M, Eckardt K-U (2021) Novichok nerve agent poisoning. Lancet 397:249–252
pubmed: 33357496 doi: 10.1016/S0140-6736(20)32644-1 pmcid: 33357496
Tenberken O, Mikler J, Hill I, Weatherby K, Thiermann H, Worek F, Reiter G (2010a) Toxicokinetics of tabun enantiomers in anaesthetized swine after intravenous tabun administration. Toxicol Lett 198:177–181
pubmed: 20599598 doi: 10.1016/j.toxlet.2010.06.012 pmcid: 20599598
Tenberken O, Thiermann H, Worek F, Reiter G (2010b) Chromatographic preparation and kinetic analysis of interactions between tabun enantiomers and acetylcholinesterase. Toxicol Lett 195:142–146
pubmed: 20347021 doi: 10.1016/j.toxlet.2010.03.012 pmcid: 20347021
Thiermann H, Aurbek N, Worek F (2016) Treatment of nerve agent poisoning. In: Worek F, Jenner J, Thiermann H (eds) Chemical warfare toxicology. Royal Society of Chemistry, Cambridge, pp 1–42
Tsai P, Bigley A, Li Y, Ghanem E, Cadieux C, Kasten S, Reeves T, Cerasoli D, Raushel F (2010) Stereoselective hydrolysis of organophosphate nerve agents by the bacterial phosphotriesterase. Biochemistry 49:7978–7987
pubmed: 20701311 doi: 10.1021/bi101056m pmcid: 20701311
Tsai P, Fox N, Bigley A, Harvey S, Barondeau D, Raushel F (2012) Enzymes for the homeland defense: optimizing phosphotriesterase for the hydrolysis of organophosphate nerve agents. Biochemistry 51:6463–6475
pubmed: 22809162 doi: 10.1021/bi300811t pmcid: 22809162
Wilkins M, Gasteiger E, Bairoch A, Sanchez J, Williams K, Appel R, Hochstrasser D (1999) Protein identification and analysis tools in the ExPASy server. Methods Mol Biol 112:531–552
pubmed: 10027275 pmcid: 10027275
Wille T, Neumaier K, Koller M, Ehinger C, Aggarwal N, Ashani Y, Goldsmith M, Sussman JL, Tawfik DS, Thiermann H, Worek F (2016) Single treatment of VX poisoned guinea pigs with the phosphotriesterase mutant C23AL: intraosseous versus intravenous injection. Toxicol Lett 258:198–206
pubmed: 27397758 doi: 10.1016/j.toxlet.2016.07.004 pmcid: 27397758
Worek F, Seeger T, Reiter G, Goldsmith M, Ashani Y, Leader H, Sussman J, Aggarwal N, Thiermann H, Tawfik D (2014) Post-exposure treatment of VX poisoned guinea pigs with the engineered phosphotriesterase mutant C23: a proof-of-concept study. Toxicol Lett 231:45–54
pubmed: 25195526 doi: 10.1016/j.toxlet.2014.09.003 pmcid: 25195526
Worek F, Thiermann H, Wille T (2016a) Catalytic bioscavengers in nerve agent poisoning: a promising approach? Toxicol Lett 244:143–148
pubmed: 26200600 doi: 10.1016/j.toxlet.2015.07.012 pmcid: 26200600
Worek F, Wille T, Koller M, Thiermann H (2016b) Toxicology of organophosphorus compounds in view of an increasing terrorist threat. Arch Toxicol 90:2131–2145
pubmed: 27349770 doi: 10.1007/s00204-016-1772-1 pmcid: 27349770
Worek F, Thiermann H, Wille T (2020) Organophosphorus compounds and oximes: a critical review. Arch Toxicol 94:2275–2292
pubmed: 32506210 pmcid: 7367912 doi: 10.1007/s00204-020-02797-0

Auteurs

Anja Köhler (A)

Institut für Pharmakologie und Toxikologie der Bundeswehr, 80937, Munich, Germany.
Lehrstuhl für Biologische Chemie, Technische Universität München, 85354, Freising, Germany.

Benjamin Escher (B)

Lehrstuhl für Biologische Chemie, Technische Universität München, 85354, Freising, Germany.

Laura Job (L)

Lehrstuhl für Biologische Chemie, Technische Universität München, 85354, Freising, Germany.

Marianne Koller (M)

Institut für Pharmakologie und Toxikologie der Bundeswehr, 80937, Munich, Germany.

Horst Thiermann (H)

Institut für Pharmakologie und Toxikologie der Bundeswehr, 80937, Munich, Germany.

Arne Skerra (A)

Lehrstuhl für Biologische Chemie, Technische Universität München, 85354, Freising, Germany. skerra@tum.de.

Franz Worek (F)

Institut für Pharmakologie und Toxikologie der Bundeswehr, 80937, Munich, Germany. franzworek@bundeswehr.org.

Articles similaires

T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis

Prevalence and implications of fragile X premutation screening in Thailand.

Areerat Hnoonual, Sunita Kaewfai, Chanin Limwongse et al.
1.00
Humans Fragile X Mental Retardation Protein Thailand Male Female
Humans Receptors, Antigen, T-Cell Proto-Oncogene Proteins p21(ras) Pancreatic Neoplasms T-Lymphocytes

Classifications MeSH